Elizabeth R Unger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3796537/publications.pdf

Version: 2024-02-01

279 papers	15,580 citations	25034 57 h-index	20961 115 g-index

282 all docs	282 docs citations	282 times ranked	12256 citing authors

#	Article	IF	Citations
1	Prevalence of HPV Infection Among Females in the United States. JAMA - Journal of the American Medical Association, 2007, 297, 813.	7.4	1,286
2	Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 2007, 56, 1-24.	61.1	614
3	Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report, 2019, 68, 698-702.	15.1	585
4	Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 2015, 64, 300-4.	15.1	581
5	US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. Journal of the National Cancer Institute, 2015, 107, djv086.	6.3	550
6	Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003â€“2010. Journal of Infectious Diseases, 2013, 208, 385-393.	4.0	456
7	Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Services Research, 2003, 3, 25.	2.2	413
8	Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 2014, 63, 1-30.	61.1	387
9	Prevalence and Incidence of Chronic Fatigue Syndrome in Wichita, Kansas. Archives of Internal Medicine, 2003, 163, 1530.	3.8	385
10	Prevalence of Genital Human Papillomavirus Among Females in the United States, the National Health and Nutrition Examination Survey, 2003â€“2006. Journal of Infectious Diseases, 2011, 204, 566-573.	4.0	333
11	Validation of Array-Based Gene Expression Profiles by Real-Time (Kinetic) RT-PCR. Journal of Molecular Diagnostics, 2001, 3, 26-31.	2.8	280
12	Use of Real-Time Quantitative PCR to Validate the Results of cDNA Array and Differential Display PCR Technologies. Methods, 2001, 25, 443-451.	3.8	273
13	Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics, 2016, 137, e20151968.	2.1	262
14	Chronic Fatigue Syndrome â€“ A clinically empirical approach to its definition and study. BMC Medicine, 2005, 3, 19.	5.5	225
15	Viral Diagnosis by in situ Hybridization. American Journal of Surgical Pathology, 1986, 10, 1-8.	3.7	213
16	Human Papillomavirus (HPV) DNA Copy Number Is Dependent on Grade of Cervical Disease and HPV Type. Journal of Clinical Microbiology, 1999, 37, 1030-1034.	3.9	205
17	Early Adverse Experience and Risk for Chronic Fatigue Syndrome. Archives of General Psychiatry, 2006, 63, 1258.	12.3	198
18	Seroprevalence of Human Papillomavirus Type 16 Infection in the United States. Journal of Infectious Diseases, 2002, 186, 1396-1402.	4.0	192

#	Article	IF	Citations
19	National Registry for Juvenile-Onset Recurrent Respiratory Papillomatosis. JAMA Otolaryngology, 2003, 129, 976.	1.2	173
20	Association of Chlamydia trachomatis with Persistence of High-Risk Types of Human Papillomavirus in a Cohort of Female Adolescents. American Journal of Epidemiology, 2005, 162, 668-675.	3.4	163
21	Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003â€“2004. Journal of Infectious Diseases, 2009, 200, 1059-1067.	4.0	163
22	Psychometric properties of the CDC Symptom Inventory for assessment of Chronic Fatigue Syndrome. Population Health Metrics, 2005, 3, 8.	2.7	143
23	Comparison of Human Papillomavirus Detection and Typing by Cycle Sequencing, Line Blotting, and Hybrid Capture. Journal of Clinical Microbiology, 2000, 38, 651-655.	3.9	133
24	Human Papillomavirus Infection and Cervical Cytology in Women Screened for Cervical Cancer in the United States, 2003â€“2005. Annals of Internal Medicine, 2008, 148, 493.	3.9	128
25	Epidemiology of Human Papillomavirus Infection and Abnormal Cytologic Test Results in an Urban Adolescent Population. Journal of Infectious Diseases, 2004, 189, 46-50.	4.0	123
26	Prevalence of Human Papillomavirus Among Females After Vaccine Introductionâ€”National Health and Nutrition Examination Survey, United States, 2003â€“2014. Journal of Infectious Diseases, 2017, 216, 594-603.	4.0	122
27	Cervical Cancer Incidence in a Prevaccine Era in the United States, 1998â€“2002. Obstetrics and Gynecology, 2007, 109, 360-370.	2.4	111
28	Association of human papillomavirus type 16 integration in theE2 gene with poor disease-free survival from cervical cancer. International Journal of Cancer, 1997, 74, 50-56.	5.1	106
29	Synchronous carcinomas of the uterine corpus and ovary. Gynecologic Oncology, 1984, 19, 329-335.	1.4	103
30	Alterations in Diurnal Salivary Cortisol Rhythm in a Population-Based Sample of Cases With Chronic Fatigue Syndrome. Psychosomatic Medicine, 2008, 70, 298-305.	2.0	101
31	Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States â€“ 2008â€“2012. Vaccine, 2015, 33, 1608-1613.	3.8	101
32	Simultaneous Amplification and Identification of 25 Human Papillomavirus Types with Templex Technology. Journal of Clinical Microbiology, 2006, 44, 4157-4162.	3.9	100
33	Continuous-flow ferrohydrodynamic sorting of particles and cells in microfluidic devices. Microfluidics and Nanofluidics, 2012, 13, 645-654.	2.2	99
34	Immunocytochemistry is Automated: Development of A Robotic Workstation Based Upon the Capillary Action Principle. Journal of Histotechnology, 1988, 11, 165-183.	0.5	96
35	Efficient DNA Extraction for HPV Genotyping in Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2011, 13, 377-381.	2.8	95
36	Human Papillomavirus Infection and Cytologic Abnormalities of the Anus and Cervix Among HIV-Infected Women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (The SUN Study). Sexually Transmitted Diseases, 2011, 38, 253-259.	1.7	94

#	Article	IF	Citations
37	Post-licensure monitoring of HPV vaccine in the United States. Vaccine, 2010, 28, 4731-4737.	3.8	91
38	A population-based study of the clinical course of chronic fatigue syndrome. Health and Quality of Life Outcomes, 2003, 1, 49.	2.4	90
39	Human Papillomavirus Prevalence in Oropharyngeal Cancer before Vaccine Introduction, United States. Emerging Infectious Diseases, 2014, 20, 822-828.	4.3	88
40	Multicenter Study of Nucleic Acid Amplification Tests for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Children Being Evaluated for Sexual Abuse. Pediatric Infectious Disease Journal, 2009, 28, 608-613.	2.0	81
41	Human papillomavirus genotype and oropharynx cancer survival in the United States of America. European Journal of Cancer, 2015, 51, 2759-2767.	2.8	80
42	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerging Infectious Diseases, 2016, 22, 1732-1740.	4.3	77
43	Labelâ€Free and Continuousâ€Flow Ferrohydrodynamic Separation of HeLa Cells and Blood Cells in Biocompatible Ferrofluids. Advanced Functional Materials, 2016, 26, 3990-3998.	14.9	77
44	Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine, 2012, 31, 109-113.	3.8	74
45	Utility of the Blood for Gene Expression Profiling and Biomarker Discovery in Chronic Fatigue Syndrome. Disease Markers, 2002, 18, 193-199.	1.3	73
46	Factor analysis of symptoms among subjects with unexplained chronic fatigue. Journal of Psychosomatic Research, 2004, 56, 171-178.	2.6	70
47	Decreased Basal Ganglia Activation in Subjects with Chronic Fatigue Syndrome: Association with Symptoms of Fatigue. PLoS ONE, 2014, 9, e98156.	2.5	66
48	Prevalence of Genital Human Papillomavirus in Males, United States, 2013â€“2014. Journal of Infectious Diseases, 2017, 215, 1070-1079.	4.0	66
49	Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008â€“2014. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 602-609.	2.5	65
50	The Effect of Correct and Consistent Condom Use on Chlamydial and Gonococcal Infection Among Urban Adolescents. JAMA Pediatrics, 2005, 159, 536.	3.0	64
51	Sleep characteristics of persons with chronic fatigue syndrome and non-fatigued controls: results from a population-based study. BMC Neurology, 2006, 6, 41.	1.8	63
52	Population Impact of HPV Vaccines: Summary of Early Evidence. Journal of Adolescent Health, 2013, 53, 679-682.	2.5	63
53	Functional Genomics of Serotonin Receptor 2A (HTR2A): Interaction of Polymorphism, Methylation, Expression and Disease Association. NeuroMolecular Medicine, 2011, 13, 66-76.	3.4	62
54	Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction. Journal of Lower Genital Tract Disease, 2014, 18, 182-189.	1.9	62

#	Article	IF	Citations
55	Convergent Genomic Studies Identify Association of GRIK2 and NPAS2 with Chronic Fatigue Syndrome. Neuropsychobiology, 2011, 64, 183-194.	1.9	60
56	Human Papillomavirus (HPV) 6, 11, 16, and 18 Prevalence Among Females in the United Statesâ€"National Health and Nutrition Examination Survey, 2003â€"2006: Opportunity to Measure HPV Vaccine Impact?. Journal of Infectious Diseases, 2011, 204, 562-565.	4.0	60
57	Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine, 2018, 36, 4792-4799.	3.8	60
58	DNA and RNA References for qRT-PCR Assays in Exfoliated Cervical Cells. Journal of Molecular Diagnostics, 2006, 8, 113-118.	2.8	58
59	Human Papillomavirus Genotypes in High-Grade Cervical Lesions in the United States. Journal of Infectious Diseases, 2012, 206, 1878-1886.	4.0	58
60	Prevalence of Human Papillomavirus Types in Invasive Vulvar Cancers and Vulvar Intraepithelial Neoplasia 3 in the United States Before Vaccine Introduction. Journal of Lower Genital Tract Disease, 2012, 16, 471-479.	1.9	58
61	Sleep assessment in a population-based study of chronic fatigue syndrome. BMC Neurology, 2004, 4, 6.	1.8	57
62	Exercise responsive genes measured in peripheral blood of women with chronic fatigue syndrome and matched control subjects. BMC Physiology, 2005, 5, 5.	3.6	57
63	Human papillomavirus and molecular considerations for cancer risk. Cancer, 2008, 113, 2981-2994.	4.1	57
64	Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine â€" United States, 2003â€"2018. Morbidity and Mortality Weekly Report, 2021, 70, 415-420.	15.1	56
65	CDC grand rounds: Reducing the burden of HPV-associated cancer and disease. Morbidity and Mortality Weekly Report, 2014, 63, 69-72.	15.1	56
66	Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women â€" United States, 2008 and 2016. Morbidity and Mortality Weekly Report, 2019, 68, 337-343.	15.1	55
67	Association of human papillomavirus with penile carcinoma: A study using polymerase chain reaction and in situ hybridization. Human Pathology, 1991, 22, 908-913.	2.0	53
68	Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome. Journal of Translational Medicine, 2003, 1, 10.	4.4	53
69	HPV Type Attribution in High-Grade Cervical Lesions: Assessing the Potential Benefits of Vaccines in a Population-Based Evaluation in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 393-399.	2.5	51
70	Prevalence of Cervical and Oral Human Papillomavirus Infections Among US Women. Journal of Infectious Diseases, 2014, 209, 1739-1743.	4.0	50
71	Short Duration of Elevated vIRF-1 Expression during Lytic Replication of Human Herpesvirus 8 Limits Its Ability To Block Antiviral Responses Induced by Alpha Interferon in BCBL-1 Cells. Journal of Virology, 2004, 78, 6621-6635.	3.4	49
72	Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. International Journal of Cancer, 2005, 115, 114-120.	5.1	49

#	Article	IF	Citations
73	Human Papillomavirus Genotype Prevalence in Invasive Penile Cancers from a Registry-Based United States Population. Frontiers in Oncology, 2014, 4, 9.	2.8	48
74	Monitoring for Human Papillomavirus Vaccine Impact Among Gay, Bisexual, and Other Men Who Have Sex With Menâ€"United States, 2012â€"2014. Journal of Infectious Diseases, 2016, 214, 689-696.	4.0	48
75	Estimated Prevalence and Incidence of Disease-Associated Human Papillomavirus Types Among 15- to 59-Year-Olds in the United States. Sexually Transmitted Diseases, 2021, 48, 273-277.	1.7	48
76	Reproducibility of Alternative Probe Synthesis Approaches for Gene Expression Profiling with Arrays. Journal of Molecular Diagnostics, 2000, 2, 124-127.	2.8	47
77	Improved Detection of Viral RNA Isolated From Liquid-based Cytology Samples. Molecular Diagnosis and Therapy, 2001, 6, 125-130.	1.1	46
78	Identification of Phosphoglycerate Kinase 1 (PGK1) as a reference gene for quantitative gene expression measurements in human blood RNA. BMC Research Notes, 2011, 4, 324.	1.4	45
79	Human Papillomavirus Genotype Prevalence in Invasive Vaginal Cancer From a Registry-Based Population. Obstetrics and Gynecology, 2014, 123, 817-821.	2.4	45
80	Amplification of human papillomavirus types 16 and 18 in invasive cervical cancer. Human Pathology, 1995, 26, 676-681.	2.0	44
81	Perception versus polysomnographic assessment of sleep in CFS and non-fatigued control subjects: results from a population-based study. BMC Neurology, 2007, 7, 40.	1.8	44
82	Assessing the relationship between HIV infection and cervical cancer in CÃ´te d'Ivoire: A case-control study. BMC Infectious Diseases, 2010, 10, 242.	2.9	44
83	Individual and geographic disparities in human papillomavirus types 16/18 in highâ€grade cervical lesions. Cancer, 2013, 119, 3052-3058.	4.1	44
84	Populationâ€based trends in highâ€grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer, 2015, 121, 2775-2781.	4.1	44
85	Real-time PCR-based Fluorescent Assay for Quantitation of Human Papillomavirus Types 6, 11, 16, and 18. Molecular Diagnosis and Therapy, 2001, 6, 39-47.	1.1	44
86	Seroprevalence of Human Papillomavirus Type 16 in Children. Journal of Infectious Diseases, 2005, 191, 1817-1819.	4.0	43
87	Longitudinal Measures of Human Papillomavirus 6 and 11 Viral Loads and Antibody Response in Children With Recurrent Respiratory Papillomatosis. JAMA Otolaryngology, 2006, 132, 711.	1.2	43
88	Identifying illness parameters in fatiguing syndromes using classical projection methods. Pharmacogenomics, 2006, 7, 407-419.	1.3	43
89	Regional distribution of fatiguing illnesses in the United States: a pilot study. Population Health Metrics, 2004, 2, 1.	2.7	42
90	Seroprevalence of 9 Human Papillomavirus Types in the United States, 2005â€"2006. Journal of Infectious Diseases, 2016, 213, 191-198.	4.0	42

#	Article	IF	Citations
91	Automation ofIn situHybridization: Application of the Capillary Action Robotic Workstation. Journal of Histotechnology, 1988, 11, 253-258.	0.5	41
92	Non-hodgkin's lymphomas in patients with human immunodeficiency virus infection. Presence of epsteinâ€“barr virus byIn situ hybridization, clinical presentation, and follow-up. Cancer, 1991, 68, 2460-2465.	4.1	41
93	Human Papillomavirus Prevalence in Invasive Laryngeal Cancer in the United States. PLoS ONE, 2014, 9, e115931.	2.5	41
94	Anogenital Human Papillomavirus in Sexually Abused and Nonabused Children: A Multicenter Study. Pediatrics, 2011, 128, e658-e665.	2.1	40
95	Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008â€“2015. Clinical Infectious Diseases, 2019, 68, 1282-1291.	5.8	40
96	Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses. Journal of Infectious Diseases, 2020, 221, 910-918.	4.0	40
97	Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14â€“59 Years, United States, 2013â€“2014. Journal of Infectious Diseases, 2018, 217, 869-877.	4.0	39
98	Human Papillomavirus Prevalence in Invasive Anal Cancers in the United States Before Vaccine Introduction. Journal of Lower Genital Tract Disease, 2013, 17, 397-403.	1.9	37
99	Predictors of Remission in Juvenile-Onset Recurrent Respiratory Papillomatosis. JAMA Otolaryngology, 2003, 129, 1275.	1.2	36
100	Differential-display PCR of peripheral blood for biomarker discovery in chronic fatigue syndrome. Journal of Molecular Medicine, 2004, 82, 750-755.	3.9	36
101	Coping styles in people with chronic fatigue syndrome identified from the general population of Wichita, KS. Journal of Psychosomatic Research, 2006, 60, 567-573.	2.6	36
102	Bioelectronic DNA detection of human papillomaviruses using eSensorâ„¢: a model system for detection of multiple pathogens. BMC Infectious Diseases, 2003, 3, 12.	2.9	35
103	Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study. Scientific Reports, 2020, 10, 4920.	3.3	35
104	Detection of Human Papillomavirus in Archival Tissues: Comparison of In Situ Hybridization and Polymerase Chain Reaction. Journal of Histochemistry and Cytochemistry, 1998, 46, 535-540.	2.5	34
105	The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes and Control, 2012, 23, 281-288.	1.8	34
106	Declines in Vaccine-Type Human Papillomavirus Prevalence in Females Across Racial/Ethnic Groups: Data From a National Survey. Journal of Adolescent Health, 2019, 65, 715-722.	2.5	34
107	Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine, 2019, 37, 3918-3924.	3.8	34
108	Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008â€“2015. International Journal of Cancer, 2020, 146, 810-818.	5.1	34

#	Article	IF	Citations
109	Composite Hodgkin's and Non-Hodgkin's lymphoma in a patient with acquired immune deficiency syndrome. In-situ demonstration of epsteinâ€“barr virus. Cancer, 1990, 66, 796-800.	4.1	33
110	Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012â€“2013. Journal of Infectious Diseases, 2015, 212, 1970-1975.	4.0	33
111	A real-time PCR assay for HPV52 detection and viral load quantification. Clinical Laboratory, 2012, 58, 61-6.	0.5	33
112	Characterization of the Human Cervical Mucous Proteome. Clinical Proteomics, 2010, 6, 18-28.	2.1	32
113	Avian model for 13-cis-retinoic acid embryopathy: Demonstration of neural crest related defects. Teratology, 1990, 41, 463-472.	1.6	31
114	Chemiluminescent Analysis of Gene Expression on High-density Filter Arrays. Journal of Histochemistry and Cytochemistry, 1999, 47, 337-342.	2.5	31
115	Transgender Women Have Higher Human Papillomavirus Prevalence Than Men Who Have Sex With Menâ€”Two U.S. Cities, 2012â€“2014. Sexually Transmitted Diseases, 2019, 46, 657-662.	1.7	31
116	Human papillomavirus type 16 E2 and E6/E7 variants. Gynecologic Oncology, 2005, 96, 695-700.	1.4	30
117	Type-specific reproducibility of the Roche linear array HPV genotyping test. Journal of Clinical Virology, 2008, 42, 412-414.	3.1	30
118	Pathway-focused genetic evaluation of immune and inflammation related genes with chronic fatigue syndrome. Human Immunology, 2015, 76, 553-560.	2.4	30
119	Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. American Journal of Epidemiology, 2017, 185, 617-626.	3.4	30
120	Gene expression correlates of unexplained fatigue. Pharmacogenomics, 2006, 7, 395-405.	1.3	29
121	Oral sampling and human papillomavirus genotyping in HIVâ€infected patients. Journal of Oral Pathology and Medicine, 2012, 41, 288-291.	2.7	29
122	CDC Grand Rounds: Chronic Fatigue Syndrome â€” Advancing Research and Clinical Education. Morbidity and Mortality Weekly Report, 2016, 65, 1434-1438.	15.1	29
123	Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. Journal of Virological Methods, 2006, 138, 170-176.	2.1	28
124	An evaluation of exclusionary medical/psychiatric conditions in the definition of chronic fatigue syndrome. BMC Medicine, 2009, 7, 57.	5.5	28
125	Chronic fatigue syndrome: the current status and future potentials of emerging biomarkers. Fatigue: Biomedicine, Health and Behavior, 2014, 2, 93-109.	1.9	28
126	Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. Journal of Clinical Virology, 2016, 80, 36-39.	3.1	26

#	Article	IF	Citations
127	p16(INK4A) expression in invasive laryngeal cancer. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 52-55.	4.5	26
128	Vaccine Effectiveness Against Prevalent Anal and Oral Human Papillomavirus Infection Among Men Who Have Sex With Menâ€"United States, 2016â€"2018. Journal of Infectious Diseases, 2020, 222, 2052-2060.	4.0	26
129	Performance of Commercial Reverse Line Blot Assays for Human Papillomavirus Genotyping. Journal of Clinical Microbiology, 2012, 50, 1539-1544.	3.9	25
130	Minimum data elements for research reports on CFS. Brain, Behavior, and Immunity, 2012, 26, 401-406.	4.1	25
131	Analysis of 16S rRNA gene sequences and circulating cell-free DNA from plasma of chronic fatigue syndrome and non-fatigued subjects. BMC Microbiology, 2002, 2, 39.	3.3	24
132	HPV Genotypes in High Grade Cervical Lesions and Invasive Cervical Carcinoma as Detected by Two Commercial DNA Assays, North Carolina, 2001â€"2006. PLoS ONE, 2012, 7, e34044.	2.5	24
133	In Situ Diagnosis of Human Papillomaviruses. Clinics in Laboratory Medicine, 2000, 20, 289-301.	1.4	23
134	Effect of storage temperatures on the stability of cytokines in cervical mucous. Cytokine, 2007, 37, 176-179.	3.2	23
135	Evaluation of the Rapid BioStar Optical Immunoassay for Detection of Chlamydia trachomatis in Adolescent Women. Journal of Clinical Microbiology, 2009, 47, 215-216.	3.9	23
136	Oral Human Papillomavirus Is Common in Individuals with Fanconi Anemia. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 864-872.	2.5	23
137	Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States. Clinical Infectious Diseases, 2021, 73, 885-890.	5.8	23
138	International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine, 2012, 30, 294-299.	3.8	22
139	Patterns of cellular and HPV 16 methylation as biomarkers for cervical neoplasia. Journal of Virological Methods, 2012, 184, 84-92.	2.1	22
140	Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009â€"2012. Preventive Medicine, 2017, 103, 60-65.	3.4	22
141	An Isothermal, Multiplex Amplification Assay for Detection and Genotyping of Human Papillomaviruses in Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2020, 22, 419-428.	2.8	22
142	Impact of RNA extraction from limited samples on microarray results. BioTechniques, 2003, 35, 968-973.	1.8	21
143	Exploration of neuroendocrine and immune gene expression in peripheral blood mononuclear cells. Molecular Brain Research, 2004, 129, 193-197.	2.3	21
144	Seroepidemiology of Human Papillomavirus Type 11 in the United States: Results From the Third National Health and Nutrition Examination Survey, 1991â€"1994. Sexually Transmitted Diseases, 2008, 35, 298-303.	1.7	21

#	Article	IF	Citations
145	Optimization of SELDI-TOF protein profiling for analysis of cervical mucous. Journal of Proteomics, 2009, 71, 637-646.	2.4	21
146	Multiscale analysis of heart rate variability in non-stationary environments. Frontiers in Physiology, 2013, 4, 119.	2.8	21
147	Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the USA, National Health and Nutrition Examination Surveys, 2003â€“2006: TableÂ1. Sexually Transmitted Infections, 2014, 90, 505-508.	1.9	21
148	Improved detection of viral RNA isolated from liquid-based cytology samples. Molecular Diagnosis and Therapy, 2001, 6, 125-130.	1.1	21
149	Characterization of RNA in cytologic samples preserved in a methanol-based collection solution*, **. Molecular Diagnosis and Therapy, 1998, 3, 67-72.	1.1	20
150	Correlates of cervical mucosal antibodies to human papillomavirus 16: Results from a case control study. Gynecologic Oncology, 2005, 99, S262-S268.	1.4	20
151	Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18. American Journal of Epidemiology, 2020, 189, 265-276.	3.4	20
152	Real-time PCR-based fluorescent assay for quantitation of human papillomavirus types 6, 11, 16, and 18. Molecular Diagnosis and Therapy, 2001, 6, 39-47.	1.1	20
153	Human Papillomavirus Vaccine Impact and Effectiveness Through 12 Years After Vaccine Introduction in the United States, 2003 to 2018. Annals of Internal Medicine, 2022, 175, 918-926.	3.9	20
154	Human papillomavirus type 16 variant assignment by pyrosequencing. Journal of Virological Methods, 2006, 136, 166-170.	2.1	19
155	Gene expression profile of cervical tissue compared to exfoliated cells: Impact on biomarker discovery. BMC Genomics, 2005, 6, 64.	2.8	18
156	HPV Prevalence among Women from Appalachia: Results from the CARE Project. PLoS ONE, 2013, 8, e74276.	2.5	18
157	Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008â€“2012. Emerging Infectious Diseases, 2015, 21, 1557-1561.	4.3	18
158	Human Papillomavirus Antibody Reference Reagents for Use in Postvaccination Surveillance Serology. Vaccine Journal, 2012, 19, 449-451.	3.1	17
159	Early menopause and other gynecologic risk indicators for chronic fatigue syndrome in women. Menopause, 2015, 22, 826-834.	2.0	17
160	Serum Immune Profiling for Early Detection of Cervical Disease. Theranostics, 2017, 7, 3814-3823.	10.0	17
161	Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. Journal of Infectious Diseases, 2018, 217, 1544-1552.	4.0	17
162	Endometriosis as a Comorbid Condition in Chronic Fatigue Syndrome (CFS): Secondary Analysis of Data From a CFS Case-Control Study. Frontiers in Pediatrics, 2019, 7, 195.	1.9	17

#	Article	IF	Citations
163	Genital human papillomaviruses among women of reproductive age in Jamaica. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2013, 33, 159-165.	1.1	17
164	Automated Immunohistochemical Estrogen Receptor in Fixed Embedded Breast Carcinomas: Comparison with Manual Immunohistochemistry on Frozen Tissues. American Journal of Clinical Pathology, 1989, 92, 669-672.	0.7	16
165	In Situ Hybridization for Human Papillomavirus DNA in Uterine Adenosquamous Carcinoma with Glassy Cell Features (â€œGlassy Cell Carcinomaâ€). American Journal of Clinical Pathology, 1992, 98, 180-187.	0.7	16
166	Optimization of a Human Papillomavirus-Specific Enzyme-Linked Immunosorbent Assay. Vaccine Journal, 2002, 9, 577-582.	3.1	16
167	Age-Group Differences in Human Papillomavirus Types and Cofactors for Cervical Intraepithelial Neoplasia 3 among Women Referred to Colposcopy. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 111-121.	2.5	16
168	Urine-based human papillomavirus DNA testing as a screening tool for cervical cancer in high-risk women. International Journal of Gynecology and Obstetrics, 2014, 124, 151-155.	2.3	16
169	Concordance Between Anal and Oral Human Papillomavirus Infections Among Young Men Who have Sex With Men. Journal of Infectious Diseases, 2017, 215, 1832-1835.	4.0	16
170	Universal Human Papillomavirus Typing Assay: Whole-Genome Sequencing following Target Enrichment. Journal of Clinical Microbiology, 2017, 55, 811-823.	3.9	16
171	Malignant fibrous histiocytoma of the trachea. Annals of Thoracic Surgery, 1990, 50, 458-459.	1.3	15
172	Overview of the CDC Cervical Cancer (Cx3) Study: An Educational Intervention of HPV Testing for Cervical Cancer Screening. Journal of Women's Health, 2014, 23, 197-203.	3.3	15
173	Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009. Cancer Causes and Control, 2014, 25, 571-581.	1.8	15
174	Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population. Oral Oncology, 2019, 91, 92-96.	1.5	15
175	Assessment of Normal Variability in Peripheral Blood Gene Expression. Disease Markers, 2002, 18, 201-206.	1.3	14
176	CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide. Emerging Infectious Diseases, 2017, 23, .	4.3	14
177	Risk Factors for Oral Human Papillomavirus Infection Among Young Men Who Have Sex With Menâ€”2 Cities, United States, 2012â€“2014. Sexually Transmitted Diseases, 2018, 45, 660-665.	1.7	14
178	Results of a Pilot Study of a Mail-Based Human Papillomavirus Self-Testing Program for Underscreened Women From Appalachian Ohio. Sexually Transmitted Diseases, 2019, 46, 185-190.	1.7	14
179	Physiological assessment of orthostatic intolerance in chronic fatigue syndrome. Journal of Translational Medicine, 2022, 20, 95.	4.4	14
180	Implementation of exon arrays: alternative splicing during T-cell proliferation as determined by whole genome analysis. BMC Genomics, 2010, 11, 496.	2.8	13

#	Article	IF	Citations
181	Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine, 2013, 31, 3019-3024.	3.8	13
182	The effect of comorbid medical and psychiatric diagnoses on chronic fatigue syndrome. Annals of Medicine, 2019, 51, 371-378.	3.8	13
183	Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 492-6.	2.5	13
184	Automated Immunohistochemical Estrogen Receptor in Fixed Embedded Breast Carcinomas. American Journal of Clinical Pathology, 1991, 95, 335-339.	0.7	12
185	Application of a Manual Capillary Action Workstation to Colorimetric In Situ Hybridization. Journal of Histotechnology, 1993, 16, 33-38.	0.5	12
186	An unusual cervical carcinoma showing exception to epitheliotropism of human papillomavirus. Human Pathology, 1999, 30, 483-485.	2.0	12
187	Global amplification of sense RNA: a novel method to replicate and archive mRNA for gene expression analysis. Genomics, 2003, 82, 491-497.	2.9	12
188	Molecular Markers for Early Detection of Cervical Neoplasia. Disease Markers, 2004, 20, 103-116.	1.3	12
189	Evaluation of genital self-sampling methods for HPV detection in males. Journal of Clinical Virology, 2013, 58, 168-175.	3.1	12
190	Two vs Three Doses of Human Papillomavirus Vaccine. JAMA - Journal of the American Medical Association, 2016, 316, 2370.	7.4	12
191	Incidence and Predictors of Abnormal Anal Cytology Findings Among HIV-Infected Adults Receiving Contemporary Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 351-360.	4.0	12
192	Juvenile-Onset Recurrent Respiratory Papillomatosis in the United States, Epidemiology and HPV Typesâ€"2015â€“2020. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 774-781.	1.3	12
193	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. Journal of the National Cancer Institute, 2022, 114, 845-853.	6.3	12
194	Avian model for 13-cis-retinoic acid embryopathy: Morphological characterization of ventricular septal defects. Teratology, 1992, 46, 533-539.	1.6	11
195	In Situ Hybridization: Principles And Diagnostic Applications in Infection. Journal of Histotechnology, 1995, 18, 203-209.	0.5	11
196	HUMAN PAPILLOMAVIRUSES. Obstetrics and Gynecology Clinics of North America, 2001, 28, 653-666.	1.9	11
197	Exploration of statistical dependence between illness parameters using the entropy correlation coefficient. Pharmacogenomics, 2006, 7, 421-428.	1.3	11
198	The association of current hormonal contraceptive use with type-specific HPV detection. Sexually Transmitted Infections, 2011, 87, 385-388.	1.9	11

#	Article	IF	Citations
199	Can clinical tests help monitor human papillomavirus vaccine impact?. International Journal of Cancer, 2013, 133, 1101-1106.	5.1	11
200	Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes and Control, 2013, 24, 403-407.	1.8	11
201	Acute Psychosocial Stress-Mediated Changes in the Expression and Methylation of Perforin in Chronic Fatigue Syndrome. Genetics & Epigenetics, 2013, 5, GEG.S10944.	2.5	11
202	Association of chronic fatigue syndrome with premature telomere attrition. Journal of Translational Medicine, 2018, 16, 44.	4.4	11
203	Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era. American Journal of Preventive Medicine, 2018, 55, 19-25.	3.0	11
204	Universal human papillomavirus typing by whole genome sequencing following target enrichment: evaluation of assay reproducibility and limit of detection. BMC Genomics, 2019, 20, 231.	2.8	11
205	Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. Vaccine, 2020, 38, 5997-6006.	3.8	11
206	Sensitivity of Self-Reported Human Papillomavirus Vaccination History Among 18- to 26-Year-Old Men Who Have Sex With Men: Seattle, WA, 2016 to 2018. Sexually Transmitted Diseases, 2022, 49, 81-85.	1.7	11
207	Effectiveness of Human Papillomavirus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women. Journal of Infectious Diseases, 2022, 225, 422-430.	4.0	11
208	Kaposi sarcoma presenting as a vulvar mass. Obstetrics and Gynecology, 1995, 86, 695-697.	2.4	10
209	Toward using National Cancer Surveillance data for preventing and controlling cervical and other human papillomavirus-associated cancers in the US. Cancer, 2008, 113, 2837-2840.	4.1	10
210	Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals. Vaccine, 2015, 33, 1953-1958.	3.8	10
211	Population-Based Assessment of HPV Genotype-Specific Cervical Cancer Survival: CDC Cancer Registry Sentinel Surveillance System. JNCI Cancer Spectrum, 2018, 2, .	2.9	10
212	Effect of Specimen Order on Chlamydia trachomatis and Neisseria gonorrhoeae Test Performance and Adequacy of Papanicolaou Smear. Journal of Pediatric and Adolescent Gynecology, 2006, 19, 23-30.	0.7	9
213	Invasive and In Situ Cervical Cancer Reported to the Vaccine Adverse Event Reporting System (VAERS). Journal of Women's Health, 2010, 19, 365-370.	3.3	9
214	Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003â€“2010. International Journal of Infectious Diseases, 2015, 33, 137-141.	3.3	9
215	Evaluation of the Vulvar Cancer Histology Code Reported by Central Cancer Registries: Importance in Epidemiology. Archives of Pathology and Laboratory Medicine, 2017, 141, 139-143.	2.5	9
216	Interphase Cytogenetic Analysis of 1q12 Satellite III DNA in Melanocytic Lesions. American Journal of Dermatopathology, 2001, 23, 176-180.	0.6	8

#	Article	IF	Citations
217	Modifying Differential Display Polymerase Chain Reaction to Detect Relative Changes in Gene Expression Profiles. Analytical Biochemistry, 2002, 306, 343-346.	2.4	8
218	The effect of time interval between referral and colposcopy on detection of human papillomavirus DNA and on outcome of biopsy. American Journal of Obstetrics and Gynecology, 2003, 188, 932-937.	1.3	8
219	Human papillomavirus in amniotic fluid. BMC Pregnancy and Childbirth, 2006, 6, 28.	2.4	8
220	Evaluation of RNA Markers for Early Detection of Cervical Neoplasia in Exfoliated Cervical Cells. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 295-301.	2.5	8
221	Differences and changes in human papillomavirus type 16 variant status in human immunodeficiency virus-positive adults are not uncommon. Journal of General Virology, 2010, 91, 2068-2072.	2.9	8
222	Prevalence of 9-Valent Human Papillomavirus Types by Race/Ethnicity in the Prevaccine Era, United States, 2003â€“2006. Sexually Transmitted Diseases, 2016, 43, 633-636.	1.7	8
223	Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals. Vaccine, 2018, 36, 881-889.	3.8	8
224	Simultaneous extraction of mRNA and microRNA from whole blood stabilized in tempus tubes. BMC Research Notes, 2019, 12, 39.	1.4	8
225	Seroprevalence of Human Papillomavirus 6/11/16/18 Among Self-identified Gay/Bisexual Men Who Have Sex With Men, Men Who Have Sex With Women, and Females, United States, 2003â€“2010. Clinical Infectious Diseases, 2019, 69, 1011-1018.	5.8	8
226	Comparison of a VLPâ€based and GSTâ€L1â€based multiplex immunoassay to detect vaccineâ€induced HPVâ€specific antibodies in firstâ€void urine. Journal of Medical Virology, 2020, 92, 3774-3783.	5.0	8
227	High-Grade Vulvar, Vaginal, and Anal Precancers Among U.S. Adolescents and Young Adults After Human Papillomavirus Vaccine Introduction. American Journal of Preventive Medicine, 2022, 62, 95-99.	3.0	8
228	Type-specific HPV and Pap test results among low-income, underserved women: providing insights into management strategies. American Journal of Obstetrics and Gynecology, 2014, 211, 354.e1-354.e6.	1.3	7
229	Description of a novel multiplex avidity assay for evaluating HPV antibodies. Journal of Immunological Methods, 2017, 447, 31-36.	1.4	7
230	Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later â€“ an exploratory study. Human Vaccines and Immunotherapeutics, 2019, 15, 503-507.	3.3	7
231	Pilot Study of Markers for High-grade Anal Dysplasia in a Southern Cohort From the Womenâ€™s Interagency Human Immunodeficiency Virus Study. Clinical Infectious Diseases, 2020, 70, 1121-1128.	5.8	7
232	Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN Study. Journal of Infectious Diseases, 2020, 222, 234-242.	4.0	7
233	Recurrent respiratory papillomatosis: bright prospects for vaccine-based prevention. Papillomavirus Report, 2005, 16, 333-338.	0.2	7
234	Primary and Secondary Prevention of Cervical Cancer--Opportunities and Challenges. Journal of the National Cancer Institute, 2009, 101, 439-440.	6.3	6

#	Article	IF	Citations
235	Impact of HPV Assay on Observed Population Prevalence. Diagnostic Molecular Pathology, 2011, 20, 101-104.	2.1	6
236	Sensitive and Specific Peak Detection for SELDI-TOF Mass Spectrometry Using a Wavelet/Neural-Network Based Approach. PLoS ONE, 2012, 7, e48103.	2.5	6
237	Sexual Positioning Practices and Anal Human Papillomavirus Infection Among Young Men Who Have Sex with Men and Transgender Womenâ€"Chicago, Illinois, 2016â€"2018. Sexually Transmitted Diseases, 2021, 48, 709-713.	1.7	6
238	Latent epstein-barr virus infection is an unlikely event in the pathogenesis of immunoproliferative small intestinal disease. Cancer, 1994, 74, 1699-1705.	4.1	5
239	Gene expression profiling of dysplastic differentiation in cervical epithelial cells harboring human papillomavirus 16. Genomics, 2005, 85, 727-738.	2.9	5
240	A pilot registry of unexplained fatiguing illnesses and chronic fatigue syndrome. BMC Research Notes, 2013, 6, 309.	1.4	5
241	Pathobiology of human papillomaviruses in human immunodeficiency virus â€" Infected persons. Seminars in Diagnostic Pathology, 2017, 34, 364-370.	1.5	5
242	A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIXÂ®) in female school students in Thailand. PLoS ONE, 2022, 17, e0267294.	2.5	5
243	A Response to Jason et al. (2009), â€œEvaluating the Centers for Disease Controlâ€™s Empirical Chronic Fatigue Syndrome Case Definitionâ€• Journal of Disability Policy Studies, 2010, 20, 229-232.	1.5	4
244	HPV genotypes detected in cervical cancers from Alaska Native women, 1980â€"2007. International Journal of Circumpolar Health, 2013, 72, 21115.	1.2	4
245	Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure. Vaccines, 2020, 8, 348.	4.4	4
246	Bioinformatics Pipeline for Human Papillomavirus Short Read Genomic Sequences Classification Using Support Vector Machine. Viruses, 2020, 12, 710.	3.3	4
247	Human Papillomavirus Persistence and Association With Recurrent Cervical Intraepithelial Neoplasia After Cryotherapy vs Loop Electrosurgical Excision Procedure Among HIV-Positive Women. JAMA Oncology, 2021, 7, 1514.	7.1	4
248	In situ hybridization: Principles and practice. Clinical Immunology Newsletter, 1990, 10, 120-126.	0.1	3
249	In situ and northern hybridizations. Cancer, 1992, 69, 1532-1535.	4.1	3
250	Human papilloma virions in the laboratory. Journal of Clinical Virology, 2014, 61, 196-198.	3.1	3
251	Response to Pendleton et al. regarding reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States. Vaccine, 2016, 34, 201.	3.8	3
252	Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia. Vaccine, 2017, 35, 6712-6719.	3.8	3

#	Article	IF	Citations
253	Human Papillomavirus Oral- and Sero- Positivity in Fanconi Anemia. Cancers, 2021, 13, 1368.	3.7	3
254	Seroprevalence of Human Papillomavirus (HPV) Type 6, 11, 16, 18, by Anatomic Site of HPV Infection, in Women Aged 16-64 Years living in the Metropolitan Area of San Juan, Puerto Rico. Puerto Rico Health Sciences Journal, 2018, 37, 26-31.	0.2	3
255	Would Young Women Attending Sexually Transmitted Disease Clinics Benefit From Human Papillomavirus Vaccination? An Assessment of Human Papillomavirus DNA and Seropositivity From Human Papillomavirus Sentinel Surveillance, 2003â€“2005. Sexually Transmitted Diseases, 2014, 41, 46-49.	1.7	2
256	Precision Medicine Requires Precision Laboratories. Journal of Molecular Diagnostics, 2017, 19, 226-229.	2.8	2
257	NanoString Technology for Human Papillomavirus Typing. Viruses, 2021, 13, 188.	3.3	2
258	Prevalence of Human Papillomavirus Among Women Older than Recommended Age for Vaccination by Birth Cohort, United States 2003â€’2016. Journal of Infectious Diseases, 2022, 225, 94-104.	4.0	2
259	Prevalence of human papillomavirus genotypes in highâ€grade cervical precancer and invasive cervical cancer from cancer registries before and after vaccine introduction in the United States. Cancer, 2021, 127, 3614-3621.	4.1	2
260	Increases in Human Papillomavirus Testing Preceding Diagnosis of Cervical Precancer in 5 US States, 2008â€“2016. Journal of Lower Genital Tract Disease, 2021, 25, 192-198.	1.9	2
261	Changes in Cervical Cytology Results and Human Papillomavirus Types Among Persons Screened for Cervical Cancer, 2007 and 2015â€“2017. Journal of Lower Genital Tract Disease, 2022, 26, 135-139.	1.9	2
262	In Situ Hybridization. , 2010, , 71-79.		1
263	Lack of HPV 16 and 18 detection in serum of colposcopy clinic patients. Journal of Clinical Virology, 2011, 50, 342-344.	3.1	1
264	Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials. Human Vaccines and Immunotherapeutics, 2020, 16, 590-594.	3.3	1
265	Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity. Human Vaccines and Immunotherapeutics, 2020, 16, 1802-1807.	3.3	1
266	Human Papillomavirus and Cervical Cancer. Emerging Infectious Diseases, 2004, , .	4.3	1
267	Chlamydia Trachomatis and Human Papillomavirus Serostatus in Puerto Rican Women. Puerto Rico Health Sciences Journal, 2020, 39, 28-33.	0.2	1
268	DNA Technology. Laboratory Medicine, 1994, 25, 675-676.	1.2	0
269	Detection of Human Papillomaviruses by Polymerase Chain Reaction and In Situ Hybridization. , 2001, 49, 271-300.		0
270	Molecular Characterization of Human Papillomaviruses by PCR and <I>In Situ</i> Hybridization. , 2004, 97, 159-180.		0

#	Article	IF	Citations
271	Reply to Groner et al and Pei et al. Journal of Infectious Diseases, 2014, 209, 1304-1305.	4.0	0
272	A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States. Vaccine, 2020, 38, 6585-6591.	3.8	0
273	Sexual Mixing Patterns and Anal Human Papillomavirus Among Young Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women in 2 Cities in the United States, 2012â€“2014. Sexually Transmitted Diseases, 2020, 47, 473-480.	1.7	0
274	Genital Human Papillomavirus Prevalence Over the Lifespan Among Females and Males in a National Cross-Sectional Survey, United States, 2013â€“2016. Sexually Transmitted Diseases, 2021, 48, 855-863.	1.7	0
275	Human Papillomaviruses. , 2001, , 305-314.		0
276	Controlling for Population Variances in Health and Exposure Risk Using Randomized Matrix Based Mathematical Modeling. Lecture Notes in Computer Science, 2013, , 184-192.	1.3	0
277	Assessment of ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome): A Case Study for Health Care Providers. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2016, 12, 10527.	1.2	0
278	Evaluation of NanoString Technology for Detection and Genotyping of Human Papillomavirus (HPV). FASEB Journal, 2019, 33, lb55.	0.5	0
279	Comparing Human Papillomavirus Prevalence in Rectal and Anal Cancer Using US Cancer Registries, 2014-2015. Journal of Registry Management, 2019, 46, 128-132.	0.1	0